October-September 2016 Top Social Media News Save

In August, September and October 2016, RheumNow published 253 social media “tweets” regarding news, research and journal articles that impact the rheumatology community. These news items had a reach (impressions) of 231,000 with 228 mentions, and over 10,000 website visits to RheumNow.com. The average daily “tweet” from RheumNow is seen by 3000-4,000, with as many as 97,000 viewers (impression) from a single tweet. Our social media feeds is just one of several ways we deliver information to over 2500 rheumatologists and 3237 followers on Twitter.

The following is a list of top tweets in September and October 2016 and was selected based on the number of clicks, retweets and likes by the viewership.

1. The TaSER study, involving 111 RA patients showed that Ultrasound driven T2T treatment strategy was no more effective than DAS28 driven T2T outcomes. This is the 2nd study (ARTIC study) to shows that imaging based remission may be more sensitive but is not superior to traditional clinical measures of remission in ultimate outcomes. http://buff.ly/2dKdeBx 10/5 This was posted on 10/8/16 and viewed by 40,800 people.
2. Pregabalin (Lyrica) shown to be effective in treating abdominal pain associated with irritable bowel syndrome. http://buff.ly/2dK070K This was posted on 10/14 and 10/23/16 and had 24,900 impressions.
3. Good news in scleroderma: new trials of the endocannabinoid, Resunab (JBT-101) are in progress. Resunab has been shown to decreases TGF-B & collagen deposition. http://buff.ly/2dVgCcF Published on 10/10/16, and had a reach of 22,000.
4. Dr. Sergio Schwartzman blogs and comments on new ocular screening guidelines for hydroxychloroquine. He’s not on board with the guidelinesrecommended HCQ eye exams every 5 year based on one trial only. buff.ly/2exkLk5  This was seen on 10/17/16 and 10/23/16 and viewed by a total of 12,900.
5. The EMA and FDA have granted “orphan” status to nintedanib for Scleroderma. Nintedanib is a kinase inhibitor;currently approved for interstitial lung disease. There is now a PSS trial in progress. buff.ly/2cB7aJs Posted on 9/13/16 and viewed by 12,600
6. TNF inhibitor-induced Psoriasis can be treated with drug discontinuation, another TNFi, or ustekinumab. Use of another TNFi results in 48-85% risk of recurrence. Good readable review. http://buff.ly/2cpVWpL Posted on 9/14/15 this post was seen by 12,600.
7. Good review of CRMO (chronic recurrent multifocal osteomyelitis): manifest as multifocal bone pain and lesions on xray with high CRP. Bone biopsy is negative for cultures and shows inflammatory changes. http://buff.ly/2cnTdyX Published on 9/3/16, it was seen by 11,700 on Twitter.
8. Up to 63% have some MTX toxicity; In 22% its mod-severe. Giving caffeine at time of MTX (coffee, Dk chocolate) showed 55% improved!! buff.ly/2caOr6T Posted on 9/7/16 with a total of 10,200 impressions.
9. A recent systematic review of gout shows that allopurinol treatment significantly lowers systolic and diastolic BP & creatinine levels http://buff.ly/2d20kZO 10/9 Posted on 10/9/16 and seen by 7500
10. Medicare study shows there is no increased risk of breast cancer in RA or IBD women who are taking MTX, 6-MP or TNF inhibitors. http://buff.ly/2dYU4nb 10/12 Published on 10/12/16 it was viewed by 7500.
11. Pegloticase failure may be linked to development anti-PEG Abs, thus the reason for watching for a significant rise in serum urate. Case report shows that anti-PEG Abs may be suppressed with azathioprine; making pegloticase better tolerated. http://buff.ly/2cnlqBn Posted on 9/22/16 and viewed by 7000